ARTICLE | Product Development
Why Lilly chose NIH’s COVID-19 master protocol for Olumiant
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 15, 2020 12:36 AM UTC
Eli Lilly's decision to evaluate rheumatoid arthritis drug Olumiant baricitinib via NIH's COVID-19 master protocol highlights the model’s value for companies during the pandemic. It also raises a series of questions about how companies will approach pricing and distribution of on-patent drugs that prove useful in the fight against COVID-19.
Eli Lilly and Co. (NYSE:LLY) announced last week that its JAK-1/JAK-2 inhibitor was added to NIH’s Adaptive COVID-19 Treatment Trial master protocol, making it just the second drug after remdesivir from Gilead Sciences Inc. (NASDAQ:GILD) chosen for the trial. ...